Solriamfetol, which will be branded as Sunosi, has been backed for the treatment of excessive sleepiness in adult patients with narcolepsy and obstructive sleep apnea (OSA), according to a  statement from the European Medicines Agency’s human medicines committee (CHMP).

The drug was approved in the United States earlier this year and is part of the company’s attempts to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, which faced a setback last year.

While final approvals are done by the European Commission, it generally follows the panel’s recommendation and announces its decision within a couple of months.